Kane Biotech (KNE) Price & Analysis

Compare

1 Followers

KNE Stock Chart & Stats

Day’s Range― - ―

52-Week RangeC$0.04 - C$0.16

Previous CloseN/A

Volume199.87K

Average Volume (3M)78.67K

Market Cap

C$6.63M

Enterprise ValueC$20.47M

Total Cash (Recent Filing)C$493.58K

Total Debt (Recent Filing)C$2.08M

Price to Earnings (P/E)―

Beta0.32

Next Earnings

Aug 28, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding165,771,560

10 Day Avg. Volume85,143

30 Day Avg. Volume78,671

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusHold

Number of Analyst Covering1

Kane Biotech News

Kane Biotech Highlights Promising revyve® Findings at Wound Care Conferences

Kane Biotech ( ($TSE:KNE) ) has provided an announcement. Kane Biotech recently showcased promising preclinical and clinical findings...

15d ago

Kane Biotech to Showcase Innovations at Advanced Wound Care Summit

Kane Biotech ( ($TSE:KNE) ) just unveiled an update. Kane Biotech announced that its Interim CEO, Dr. Robert...

1M ago

Kane Biotech Converts Loan to Debenture and Announces AGM Results

The latest update is out from Kane Biotech ( ($TSE:KNE) ). Kane Biotech has converted a $1 million...

2M ago

Kane Biotech Reorganizes Distribution and Financial Strategies Amid Clinical Advancements

An announcement from Kane Biotech ( ($TSE:KNE) ) is now available. Kane Biotech has terminated its distribution agreement...

2M ago

Kane Biotech Reports Q1 2025 Results Amid Restructuring Efforts

The latest update is out from Kane Biotech ( ($TSE:KNE) ). Kane Biotech reported a significant increase in...

3M ago

Kane Biotech Secures $2.2 Million Through Private Placement and Insider Loan

The latest update is out from Kane Biotech ( ($TSE:KNE) ). Kane Biotech has successfully closed a private...

3M ago

Kane Biotech Reports 2024 Financials, Refocuses Strategy and Announces Leadership Change

Kane Biotech ( ($TSE:KNE) ) has provided an update. Kane Biotech reported its financial results for the fourth...

4M ago

Kane Biotech Revises Marketing Agreement with Outside the Box Capital

Kane Biotech ( ($TSE:KNE) ) has shared an announcement. Kane Biotech has announced the termination of its previous...

4M ago

Kane Biotech Secures Approval for DispersinB® Acne Trial

An announcement from Kane Biotech ( ($TSE:KNE) ) is now available. Kane Biotech has received approval from the...

5M ago

Kane Biotech Partners with Best Buy Medical for Canadian Distribution of revyve™ Wound Gel

Kane Biotech ( ($TSE:KNE) ) has issued an update. Kane Biotech has entered into a three-year distribution agreement...

5M ago

KNE FAQ

What was Kane Biotech’s price range in the past 12 months?

Kane Biotech lowest stock price was C$0.04 and its highest was C$0.16 in the past 12 months.

What is Kane Biotech’s market cap?

Kane Biotech’s market cap is C$6.63M.

When is Kane Biotech’s upcoming earnings report date?

Kane Biotech’s upcoming earnings report date is Aug 28, 2025 which is in 14 days.

How were Kane Biotech’s earnings last quarter?

Currently, no data Available

Is Kane Biotech overvalued?

According to Wall Street analysts Kane Biotech’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Kane Biotech pay dividends?

Kane Biotech does not currently pay dividends.

What is Kane Biotech’s EPS estimate?

Kane Biotech’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kane Biotech have?

Kane Biotech has 165,771,560 shares outstanding.

What happened to Kane Biotech’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Kane Biotech?

Currently, no hedge funds are holding shares in TSE:KNE

Company Description

Kane Biotech

Kane Biotech Inc. (KNE) is a biotechnology company based in Canada that specializes in the development of innovative antimicrobial products aimed at addressing biofilm-related challenges in healthcare and consumer markets. The company focuses on creating solutions that prevent and treat infections, particularly those caused by antibiotic-resistant bacteria. Kane Biotech's core products include its proprietary antimicrobial technologies, which are applicable in various sectors such as medical devices, dental care, and veterinary products.

Kane Biotech (KNE) Earnings & Revenues

Historic Earnings Reports

KNE Stock 12 Month Forecast

Average Price Target

―

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"NaN":"―"}},"plotLines":[{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":null,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">―</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">―</span>\n  </div></div>","useHTML":true}}],"tickPositions":[null,null,null,null,null],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.04,0.036923076923076927,0.033846153846153845,0.03076923076923077,0.027692307692307693,0.024615384615384615,0.02153846153846154,0.018461538461538463,0.015384615384615385,0.012307692307692308,0.00923076923076923,0.006153846153846156,0.0030769230769230813,{"y":null,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.12,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.15,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.14,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.16,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.12,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.13,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.12,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.11,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":0.11,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.08,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.06,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.05,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.04,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >